Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled time : 19:00 save search
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.7013 -17.98% 370K
|
n/a
|
| O: -7.45%
H: 0.0%
C: 0.0%
hepatitis vaccine license granted biopharma virus trial
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $165.97 0.8% 3.1M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq positive cell results study
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Published: 2024-04-11 (Crawled : 19:00) - globenewswire.com
ENLV | $1.4 64K
|
Health Technology
|
| O: 3.28%
H: 2.12%
C: -16.4%
topline trial results
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
Published: 2024-04-04 (Crawled : 19:00) - biospace.com/
HALB | $0.008 220K
|
n/a
|
| O: 3.49%
H: 7.23%
C: 1.2%
contract research trial
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
MRNA S | $101.22 -0.77% 1.8M
|
Health Technology
|
| O: -0.59%
H: 2.09%
C: -1.74%
rna-3927 mrna therapy
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
MEIP | $3.275 0.77% 26K
|
Health Technology
|
| O: -1.08%
H: 1.9%
C: 0.78%
pharma update leukemia study
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
Published: 2024-03-20 (Crawled : 19:00) - biospace.com/
LIVN | $52.115 -1.22% 190K
|
Health Technology
|
| O: 1.81%
H: 11.57%
C: 10.5%
success positive trial study
Stryve and Bitcoin – Creative Strategies to Generate Consumer Awareness, Drive Trial, and Build Loyalty – BTC Sweepstakes Announced
Published: 2024-03-05 (Crawled : 19:00) - globenewswire.com
SNAX | $1.42 -1.78% 20K
|
|
| O: 1.57%
H: 4.04%
C: -1.55%
HII Completes Initial Sea Trials of Virginia-Class Submarine New Jersey (SSN 796)
Published: 2024-02-29 (Crawled : 19:00) - globenewswire.com
HII | $271.71 1.07% 150K
|
Electronic Technology
|
| O: -0.3%
H: 0.74%
C: 0.59%
trials
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-02-27 (Crawled : 19:00) - globenewswire.com
GANX | $3.1 -1.59% 44K
|
Professional, Scientific, and T...
|
| O: 0.22%
H: 3.45%
C: -3.88%
gt-0228 disease parkinson’s trial therapeutics therapy
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
Published: 2024-02-12 (Crawled : 19:00) - biospace.com/
ANTX | $2.43 2.1% 60K
|
|
| O: -73.3%
H: 14.23%
C: -4.49%
lung disease trial
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action - ILMN
Published: 2023-12-26 (Crawled : 19:00) - prnewswire.com
LICY | $0.6232 -10.98% 3M
|
|
| O: 1.22%
H: 4.4%
C: 0.73%
OTLK P | $8.01 -3.38% 210K
|
Health Technology
|
| O: 12.11%
H: 0.0%
C: -7.48%
ILMN | $117.07 0.33% 740K
|
Health Technology
|
| O: 0.62%
H: 0.88%
C: 0.72%
deadline trial
ROSEN, LEADING TRIAL ATTORNEYS, Encourages SolarEdge Technologies, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SEDG
Published: 2023-12-26 (Crawled : 19:00) - prnewswire.com
PAYC 4 | $185.1 0.12% 230K
|
Technology Services
|
| O: -0.06%
H: 0.56%
C: -0.24%
SEDG 4 | $56.265 -1.96% 850K
|
Producer Manufacturing
|
| O: 0.65%
H: 0.05%
C: -1.19%
ILMN | $117.07 0.33% 740K
|
Health Technology
|
| O: 0.62%
H: 0.88%
C: 0.72%
deadline trial
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Paycom Software, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - PAYC
Published: 2023-12-26 (Crawled : 19:00) - prnewswire.com
PAYC 4 | $185.1 0.12% 230K
|
Technology Services
|
| O: -0.06%
H: 0.56%
C: -0.24%
SEDG 4 | $56.265 -1.96% 850K
|
Producer Manufacturing
|
| O: 0.65%
H: 0.05%
C: -1.19%
ILMN | $117.07 0.33% 740K
|
Health Technology
|
| O: 0.62%
H: 0.88%
C: 0.72%
first trusted deadline trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages National Instruments Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - NATI
Published: 2023-12-26 (Crawled : 19:00) - prnewswire.com
EL 4 | $144.34 -0.33% 1.3M
|
Consumer Non-Durables
|
| O: 0.3%
H: 0.68%
C: 0.19%
corporation deadline trial
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
Published: 2023-12-05 (Crawled : 19:00) - globenewswire.com
PFE A | $25.91 2.05% 22M
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: -1.03%
ARVN | $34.02 -0.79% 250K
|
Health Technology
|
| O: 5.35%
H: 26.96%
C: 24.13%
ibrance program trial
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
Published: 2023-11-27 (Crawled : 19:00) - biospace.com/
ACAD | $16.74 -1.93% 560K
|
Health Technology
|
| O: -0.45%
H: 0.41%
C: -0.32%
acp-204 disease alzheimer’s treatment pharmaceuticals trial phase 2
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
Published: 2023-11-27 (Crawled : 19:00) - biospace.com/
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: 0.64%
H: 0.02%
C: -0.66%
PTGX | $25.125 -0.38% 170K
|
Health Technology
|
| O: -0.58%
H: 2.19%
C: 1.69%
jnj-2113 psoriasis
The effect of deep repetitive transcranial magnetic stimulation with an H1 coil on hopelessness in patients with major depressive disorder: A randomized controlled trial
Published: 2023-11-22 (Crawled : 19:00) - brainsway.com
BWAY | $4.84 1.04% 33K
|
Health Technology
| Email alert
Add to watchlist
BRSYF | $2.47 -4.22% 250
|
n/a
| Email alert
Add to watchlist
trial
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
Published: 2023-11-10 (Crawled : 19:00) - biospace.com/
EXEL | $22.28 -0.93% 960K
|
Health Technology
|
| O: -0.1%
H: 0.33%
C: 0.0%
ellar-001 kidney cancer expansion trial results
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.